肾移植患者术后早期应用霉酚酸酯的临床观察

目的 观察肾移植术后早期不同剂量霉酚酸酯（ＭＭＦ）与环孢素Ａ（ＣｓＡ）和泼尼松（Ｐｒｅｄ）联用预防急性排斥反应的效果及安全性。方法 将６４例肾移植患者分为３组，分别给予ＭＭＦ２．０ｇ／ｄ（Ａ组）、１．５ｇ／ｄ（Ｂ组）及Ａｚａ ５０～１００ｍｇ／ｄ（Ｃ组），每组均联用ＣｓＡ及Ｐｒｅｄ（剂量相同）。观察肾移植术后６个月内急性排斥反应的发生率、移植肾功能及药物的副作用。结果 Ａ、Ｂ、Ｃ组急性排斥反应的发

Clinical observation on the early application of Cellcept following cadaveric renal transplantation

Objectives To investigate the efficiency and safety of combined use of different doses of Cellcept (MMF) with CsA and Pred at the early stage after renal transplantation for preventing and treating the acute renal allograft rejection. Methods Sixty-four cadaveric renal transplant recipients were randomly divided into 3 groups, receiving MMF 2.0 *!g/d, CsA and Pred (group A), MMF 1.5 *!g/d, CsA and Pred (group B) and Aza 50 to 100*!mg/d, CsA and Pred (group C) respectively. The incidence of the acute renal allograft rejection, the function of the renal graft and the different adverse effects in the recipients at the first 6 months after renal transplantation were observed. Results The incidence of the acute rejection was 11.11 *!%,0, 27.5 *!% in the groups A, B and C respectively. The frequency of diarrhea was the highest in the group A, and other side events were similar among the three groups. Conclusions Combined use of different doses of MMF with CsA and Pred could effectively prevent the occurrence of acute rejection at the early stage after transplantation. Except for the side events of gastrointestine, other MMF-induced side effects was not increased.